The World Health Organization released the Global Tuberculosis Report 2026 on 12 November 2026. The report says India cut TB deaths by 38 percent between 2015 and 2025, better than the global fall of 35 percent, and recorded a 94 percent treatment success rate for drug-susceptible TB. It also estimates that 10.6 million people fell ill with TB in 2025, which keeps TB as the leading cause of death from a single infection.
What Is Tuberculosis and How Does It Spread?
Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It most often affects the lungs and spreads through the air when a person with lung TB coughs, sneezes or spits. TB is preventable and curable with antibiotics, though treatment must be completed fully.
About a quarter of the world population carries TB bacteria without falling sick. This condition is called latent TB infection. People with latent infection have no symptoms and cannot spread TB to others. Only 5 to 10 percent of them later develop active TB disease in their lifetime. Babies, young children and people with weak immunity face higher risk.
Active TB disease occurs when bacteria multiply and damage organs. Pulmonary TB affects the lungs and is the most common and infectious form. Extrapulmonary TB affects other parts such as lymph nodes, kidneys, spine and brain. Without proper treatment, active TB can be fatal.
Common symptoms of active lung TB include prolonged cough lasting more than three weeks, cough with blood or sputum, chest pain, fever, night sweats, weight loss, loss of appetite, weakness and fatigue. Symptoms depend on the organ affected. For example, TB of the spine can cause back pain, while TB of the lymph nodes can cause swelling in the neck.
Yes, TB is curable. Drug-susceptible TB is treated with a combination of antibiotics, mainly rifampicin, isoniazid, pyrazinamide and ethambutol. Patients must take medicines daily for four to six months. Stopping early is dangerous because surviving bacteria can become drug resistant and harder to kill.
The BCG vaccine, or Bacille Calmette-Guerin vaccine, is given to babies in many countries including India. It protects young children against severe forms of TB such as TB of the brain and widespread TB in the body. Its protection against lung TB in adults is limited and varies across populations.
What the Global Tuberculosis Report 2026 Says on Cases and Deaths
The WHO Global TB Programme in Geneva prepares the Global Tuberculosis Report every year. The World Health Organization, founded in 1948 and headquartered in Geneva, Switzerland, collected data for the 2026 edition from 187 countries covering more than 99 percent of the world population and TB cases.
The WHO estimates that 10.6 million people developed TB in 2025. This equals 129 new cases per 1,00,000 population. Of these, 5.7 million were adult men, 3.7 million were adult women and 1.2 million were children aged below 14 years. Treatment has saved an estimated 86 million lives since 2000.
The WHO estimates that 1.13 million people died from TB in 2025. This includes about 1 million deaths among HIV-negative people and about 1,37,000 deaths among people living with HIV. TB remains the leading cause of death from a single infectious agent and ranks 13th among all causes of death.
| Global TB indicator, 2025 | WHO estimate |
|---|---|
| People who fell ill with TB | 10.6 million |
| People who died from TB | 1.13 million |
| People diagnosed and notified | 8.4 million |
| Undiagnosed or unreported gap | 2.2 million |
| Rifampicin-resistant TB cases | 3,70,000 |
| Share on treatment among drug-resistant cases | 42 percent |
| Global treatment success, drug-susceptible TB | 90 percent |
The WHO notes two clear trends. Deaths fell by 35 percent between 2015 and 2025. This meets the first milestone of the End TB Strategy, but five years late. The plan had set this 35 percent cut for 2020 and a 75 percent cut for 2025. The TB incidence rate fell by only 14 percent between 2015 and 2025, far short of the 50 percent reduction target for 2025. The rate fell by 1.6 percent between 2024 and 2025.
Where the Global TB Burden Is Concentrated
The WHO reports that 30 high burden countries accounted for 88 percent of new TB cases in 2025. Eight countries accounted for about two thirds of the total burden. India accounted for about a quarter of global cases, followed by Indonesia at 10 percent, the Philippines at 6.8 percent, China at 6.5 percent, Pakistan at 6.4 percent, Nigeria at 4.9 percent, the Democratic Republic of the Congo at 3.9 percent and Bangladesh at 3.7 percent.
The regional pattern is uneven. South-East Asia reported 35 percent of cases, the Western Pacific 27 percent and Africa 25 percent. Between 2015 and 2025, TB incidence fell by 42 percent in Europe and 30 percent in Africa, but by only 18 percent in South-East Asia and 6.6 percent in the Eastern Mediterranean. The Western Pacific showed no net change, while the Americas recorded a 13 percent rise.
How India Cut TB Mortality by 38 Percent
The WHO estimates that TB mortality in India fell from 28 deaths per 1,00,000 population in 2015 to 18 deaths per 1,00,000 in 2025. This 38 percent fall is better than the global fall of 35 percent. India also recorded a 94 percent treatment success rate for drug-susceptible TB, higher than the global average of 90 percent.
The WHO based its India estimates on multiple Indian sources. These include the Sample Registration System of the Registrar General of India, community-based verbal autopsy studies that interview families to confirm cause of death, and programme data from Ni-kshay, the national online TB tracking portal. The Indian Council of Medical Research and the National Institute for Research in Tuberculosis conducted a nationally representative TB prevalence survey in 2025. The results have been shared with the WHO for technical review, after which the WHO will publish an updated country profile for India.
India is the highest TB burden country in the world and accounts for about a quarter of global cases. Progress therefore has global weight. Faster detection of cases without symptoms has played a large role. Active case finding with chest X-rays and rapid molecular tests helped find infections that would otherwise spread silently.
The Health Ministry links the gain to early detection, prompt treatment with quality assured drugs, technology use and continuous patient care. Nutritional support has been central because undernutrition raises TB risk and worsens treatment outcomes. Nutritional aid under Ni-kshay Poshan Yojana was raised to ₹1,000 per month per patient. Community support through the Ni-kshay Mitra initiative provides food baskets and counselling to patients during the long treatment period.
How the National TB Elimination Programme Works in India
The National TB Elimination Programme (NTEP) is the central government programme that provides free testing and quality assured treatment to all TB patients. The government renamed the Revised National TB Control Programme as NTEP in 2020 to signal the goal of eliminating TB in India by 2025, five years ahead of the global 2030 target. The programme runs as a centrally sponsored scheme under the National Health Mission and is guided by the National Strategic Plan.
The NTEP works on four pillars called Detect, Treat, Prevent and Build. Detection includes high quality testing, contact tracing in high risk groups and proactive outreach to find missing cases. Treatment includes prompt drug supply, engagement of private doctors and hospitals, and patient support. Prevention includes TB preventive treatment for household contacts, children and people living with HIV. Building refers to stronger labs, surveillance and community partnerships.
| NTEP component | What it does |
|---|---|
| Ni-kshay portal | Records details of every notified TB patient and tracks treatment |
| Ni-kshay Poshan Yojana, started in 2018 | Pays ₹1,000 per month as nutrition aid through direct benefit transfer |
| Ni-kshay Mitra under Pradhan Mantri TB Mukt Bharat Abhiyaan, launched on 9 September 2022 | Allows individuals, companies and groups to adopt patients and give food, counselling and vocational help |
| TB Mukt Bharat Abhiyan intensive campaign | Screens vulnerable groups with X-rays and rapid tests in high burden districts and villages |
The TB Mukt Bharat Abhiyan intensified the search for hidden cases. The government launched a 100-day campaign on 7 December 2024 in 347 high priority districts across 33 states and union territories and later expanded it across the country. Another focused 100-day round started on 24 March 2026, which is observed as World TB Day to mark the day in 1882 when Robert Koch announced the discovery of the TB bacterium.
Between 7 December 2024 and 8 November 2026, the Abhiyan brought more than 25 crore people under screening. Health workers conducted more than 11 crore chest X-rays using fixed machines and more than 500 hand-held X-ray units with artificial intelligence support. Labs conducted more than 3 crore nucleic acid amplification tests (NAAT), which are rapid molecular tests that detect TB bacteria quickly. The drive found 48.64 lakh new TB cases, including 14.97 lakh cases without symptoms. Early treatment of such cases helps break transmission. The government reports that 67,933 panchayats were declared TB free in 2025.
What Is the End TB Strategy and Its 2035 Target?
The End TB Strategy is the global plan adopted by the World Health Assembly in 2014 to end the TB epidemic. The World Health Assembly is the decision making body of the WHO. The strategy sets a vision of a world free of TB with zero deaths, disease and suffering.
The strategy sets three high level targets against the 2015 baseline. It also links TB control to the United Nations Sustainable Development Goals, which call for ending the TB epidemic by 2030. Target 3.3 of the goals covers TB, and TB incidence is the indicator used to track progress.
| End TB indicator | 2020 milestone | 2025 milestone | 2030 target | 2035 target |
|---|---|---|---|---|
| Fall in number of TB deaths since 2015 | 35 percent | 75 percent | 90 percent | 95 percent |
| Fall in TB incidence rate since 2015 | 20 percent | 50 percent | 80 percent | 90 percent |
| Families facing catastrophic costs due to TB | Zero | Zero | Zero | Zero |
The Global Tuberculosis Report 2026 shows mixed results. The world met the 2020 death milestone in 2025, with a 35 percent fall. But the 2025 milestones are still distant. The incidence rate fell only 14 percent against the 50 percent goal, and deaths fell 35 percent against the 75 percent goal.
The strategy rests on three pillars. The first is integrated patient centred care and prevention, including early diagnosis, universal drug susceptibility testing and preventive treatment. The second is bold policies and supportive systems, including political commitment, universal health coverage and social protection. The third is intensified research for new vaccines, rapid point of care tests and shorter drug regimens.
Why Drug-Resistant TB and Funding Gaps Remain Concerns
Drug-resistant TB develops when TB bacteria stop responding to standard drugs. The most tracked form is rifampicin-resistant TB, which includes multidrug-resistant TB. It needs longer treatment with second line medicines, close monitoring and expert care.
The WHO estimates 3,70,000 people developed rifampicin-resistant TB in 2025. Only 42 percent received treatment. Among those treated, use of the WHO recommended six month regimen rose from 18 percent in 2024 to 42 percent in 2025. Rapid testing remains weak. Only 59 percent of newly diagnosed patients received a WHO recommended rapid diagnostic test in 2025, against the global target of 100 percent by 2027. Only 8.4 million of the 10.6 million estimated cases were detected, leaving a gap of 2.2 million cases.
Money is the second concern. At the 2023 United Nations high level meeting on TB, countries agreed to mobilise $22 billion per year by 2027 for TB prevention, diagnosis and care, and $35 billion per year by 2030. They also set $5 billion per year by 2027 for TB research.
Actual funding is far lower. Total funding for TB services in low and middle income countries was $6.6 billion in 2025, up by $0.55 billion from 2024 due to higher domestic spending in India, Indonesia and Russia. Domestic sources provided 86 percent of the total. Domestic funding rose 14 percent to $5.6 billion between 2024 and 2025, while international donor funding fell 14 percent from $1.1 billion to $0.94 billion. The Global Fund to Fight AIDS, Tuberculosis and Malaria provided 79 percent of that donor funding. Research funding was $1.2 billion in 2023, less than one quarter of the $5 billion target. Twelve vaccine candidates are in clinical trials, with three in phase three, but wider progress needs faster investment.
The WHO has urged governments to protect TB budgets, expand access to prevention and rapid diagnosis, ensure complete treatment and speed up new tools. It has warned that long term cuts could lead to millions of additional cases and deaths between 2025 and 2035.
Key Takeaways
- The Global Tuberculosis Report 2026 was released by the World Health Organization on 12 November 2026 based on data from 187 countries.
- India cut TB mortality by 38 percent between 2015 and 2025, with the rate falling from 28 to 18 deaths per 1,00,000 population.
- India recorded a 94 percent treatment success rate for drug-susceptible TB, above the global average of 90 percent.
- Globally, an estimated 10.6 million people fell ill with TB and 1.13 million died in 2025, with India accounting for about a quarter of cases.
- The End TB Strategy seeks a 95 percent fall in deaths and a 90 percent fall in incidence by 2035 against 2015 levels, with zero catastrophic costs for affected families.